News

April 21, 2017 SPM-011 has been approved for prioritized review under the SAKIGAKE Designation System.
February 28, 2017 A leading-edge project we are collaboratively developing with Sumitomo Heavy Industries, the “Boron Neutron Capture Therapy (BNCT) System” has been approved for prioritized review under the SAKIGAKE Designation System.
July 14, 2016 “Notification of Commencement of Phase II Clinical Trials for Head and Neck Cancer Using Accelerator BNCT” issued.
March 24, 2016 “Concerning Third-Party Share Issuance” publicly released.
March 07, 2016 “Notification of Commencement of Phase II Clinical Trials Using Accelerator BNCT” issued.
September 06, 2012 “Notification of Commencement of World’s First Trial Using Accelerator BNCT” issued.
April 27, 2012 “The Boron Compound Demonstration and Evaluation Innovation Center—toward Cancer Boron Neutron Capturing Treatment,” a joint project of Osaka Prefecture University and Stella Pharma selected for the “Innovation Center Furtherance Project (Subsidies for Infrastructure to Demonstrate and Evaluate Leading-Edge Technology Demonstration),” a project of the Ministry of Economy, Trade and Industry.